Lyfgenia EXPLAINED with bluebird bio | SCAASF AEP 2025 скачать в хорошем качестве

Lyfgenia EXPLAINED with bluebird bio | SCAASF AEP 2025

In March's AEP session, we were joined by Sheri Reed, Associate Director of Patient and Community Education from bluebird bio, to share and educate our community on Lyfgenia, a one-time ex-vivo gene therapy approved for treating sickle cell disease in patients 12 years and older. ----------------------------------------------------- Sign up for our next session here: https://www.scaasf.org/advocacy-and-e... Visit scaasf.org for our list of programs and how we can support you. ------------------------------------------------------ The program is created for all stakeholders (clients, caregivers, medical students, medical professionals and advocates). It is designed to explore advocacy and educate to be empowered. There will be a variety of presenters’ clients, nurses, physicians and key professionals sharing and discussing issues to engage attendees. The Advocacy and Empowerment Program is comprised of two primary segments: The first portion of the webinar is designed to introduce the audience to core educational content. The second portion of the webinar is the implementation of the educational content learned, with journaling, along with discussions pertaining to real-world experiences